IE
SMMT icon

Israel Englander’s Summit Therapeutics SMMT Stock Holding History

Israel Englander’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$638K – 6432
2025
Q2 		$638K Sell
30,000
-180,000
-86% -$4.1M ﹤0.01% 4728
2025
Q1 		$4.05M Buy
+210,000
New +$4.21M ﹤0.01% 3070

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Israel Englander's SMMT Position: Q2 2026 in Review

Israel Englander increased its Summit Therapeutics (SMMT) stake by 1,760% in Q2 2026, buying an estimated $39.4M and bringing the position to 2,349,081 shares worth $34.2M. The position accounts for 0.01% of the portfolio, ranked #1172.

Israel Englander first reported a position in SMMT in Q4 2016 and has held it in 22 quarters since. The position peaked at $36.6M in Q4 2024. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Israel Englander held 2,349,081 shares of Summit Therapeutics worth $34.2M as of Q2 2026.
  • Israel Englander bought 2,222,808 Summit Therapeutics shares in Q2 2026, an estimated $39.4M.
  • Summit Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1172 holding.
  • Israel Englander first reported a position in Summit Therapeutics in Q4 2016 and has held it in 22 quarters since.
  • Israel Englander's Summit Therapeutics position peaked at $36.6M in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.